Morning Watch List: Dyax Corp. (NASDAQ:DYAX), RedHill Biopharma Ltd. (NASDAQ:RDHL), Physicians Realty Trust (NYSE:DOC), Netflix, Inc. (NASDAQ:NFLX), Akebia Therapeutics, Inc. (NASDAQ:AKBA)

Dyax Corp. (NASDAQ:DYAX) belongs to Healthcare sector. Its net profit margin is -15.30% and weekly performance is 4.14%. On last trading day company shares ended up $27.40. Dyax Corp. (NASDAQ:DYAX) distance from 50-day simple moving average (SMA50) is 5.83%. Dyax Corp. (NASDAQ:DYAX) announced that the FDA has granted Breakthrough Therapy designation to its fully human monoclonal antibody inhibitor of plasma kallikrein, DX-2930, being developed as a subcutaneous injection for the prevention of hereditary angioedema (HAE) attacks.

RedHill Biopharma Ltd. (NASDAQ:RDHL) shares moved up 0.60% in last trading session and ended the day at $18.46. RedHill Biopharma Ltd. (NASDAQ:RDHL) quarterly performance is 28.73%. On 6 July, RedHill Biopharma Ltd. (NASDAQ:RDHL) announced that it has received regulatory authorization to commence patient enrollment in Australia and New Zealand for its ongoing Phase III study with RHB-104 for Crohn’s disease (the MAP US study), and has commenced patient screening in New Zealand.

On 10 July, Physicians Realty Trust (NYSE:DOC) shares moved up 1.01% and was closed at $16.08. Physicians Realty Trust (NYSE:DOC) year to date (YTD) performance is -0.55%. Physicians Realty Trust (NYSE:DOC) announced it will release its financial results for the second quarter and year to date ended June 30, 2015, before the market opens on August 7, 2015, and will hold a conference call on this day at 10:00 a.m.

Netflix, Inc. (NASDAQ:NFLX) ended the last trading day at $680.60. Company weekly volatility is calculated as 1.98% and price to cash ratio as 13.95. Netflix, Inc. (NASDAQ:NFLX) showed a weekly performance of 3.39%. Netflix (NASDAQ:NFLX)‘s stock had its “underperform” rating reaffirmed by analysts at Wedbush in a research report issued to clients and investors on Friday, Marketbeat reports.

Akebia Therapeutics, Inc. (NASDAQ:AKBA) shares moved up 1.03% in last trading session and ended the day at $8.83. AKBA return on assets is -33.00%. Akebia Therapeutics, Inc. (NASDAQ:AKBA) quarterly performance is -15.18%. Akebia Therapeutics, Inc. (NASDAQ:AKBA), announced that John P. Butler, President and Chief Executive Officer, presented at the 2015 JMP Securities Life Sciences Conference on Tuesday, June 23 at 3:00 p.m. Eastern Time. The conference took place at The St. Regis New York in New York City.

Leave a Reply

Your email address will not be published. Required fields are marked *